A panel of Food and Drug Administration advisers on Friday unanimously endorsed an experimental Alzheimer's drug that's been shown to have modest success slowing the progression of the disease, clearing a hurdle for full agency approval.
Why it matters: Eisai and Biogen's Leqembi was found to delay cognitive decline by 27% over 18 months, but it has been plagued by safety…